Grant: Discovery Grants Program - Individual
Université de Montréal
$29,000.00
Gene delivery using a pH-sensitive molecular tweezer to catch and release nucleic acids
FY 2020-21
Summary
After a long period of latency, gene therapy has become a reality. Four gene-based products have been approved since 2015 and several are on the way. This acceleration of approvals shows that researchers have accumulated enough fundamental knowledge to support gene therapy and endorse its feasibility and clinical relevance. Currently targeting rare diseases, gene therapy products will, in the future, concern more common disease, such as cancer, and will be accessible for a larger number of patients. Nevertheless, the production and the price of this therapy is still a great challenge, and has recently conducted to the withdrawn of Glybera (1 million $/treatment). We believe that improvement could come from the delivery strategy of the therapeutic gene. Viral vectors have been commercialized, but their exorbitant production cost, biosafety issues, potential immunogenicity, limit their large-scale production. Up to now, synthetic vectors have failed in clinical trials due to insufficient efficacy and non-specific toxicity, often attributed to their positive charge.
We have recently developed pH-sensitive molecular tweezers, inspired from the biomimetic host-guest chemistry. These structures are inspired from the molecular machine field awarded by the Nobel Price in 2016. We have shown that these tweezers are able to bind a drug at physiological pH and release it at acidic pH. We also incorporated the tweezers in a lipid structure to get pH-sensitive liposomes. These nanocarriers were able to drastically improve the cytosolic delivery of hydrophilic drugs and nucleic acids in vitro and in vivo. Nevertheless, their cationic charge still limited their in vivo efficacy.
In this project, we want to develop molecular tweezers to catch and release DNA. In a first step, they will be designed for non-specific binding of nucleic acids, and will be used as a non-cationic delivery system for gene therapy products. They will be synthesized, characterized, and compared in vitro and in vivo to the latest cationic systems. In a second step, we will design DNA tweezers for the specific recognition of sequences, mismatches or trinucleotide repeats. These defects in genomic DNA are associated with a number of genetic disease such as Huntington disease or muscular dystrophy. The specificity of such tweezers will be optimized in vitro. Then, a chip-base biosensor will be developed and used as a diagnostic tool for DNA defects and genetic diseases.
Program
Discovery Grants Program - Individual
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
RGPIN-2018-05682
Name nom
Leblond Chain, Jeanne
Department département
Faculté de pharmacie
Organization id
63
Institution établissement
Université de Montréal
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2020
Competition year année de concours
2018
Award amount
29000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
1504
Committee name en
Chemistry
Committee name fr
Chimie
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
2006
Research subject group en
Materials science and technology
Research subject group fr
Science et technologie des matériaux
Research subject en
Biomaterials
Research subject fr
Biomatériaux
Installment
inst:3-5
Partie
3
Nb partie
5
Application title
Gene delivery using a pH-sensitive molecular tweezer to catch and release nucleic acids
Keyword
NSERC
Application summary
After a long period of latency, gene therapy has become a reality. Four gene-based products have been approved since 2015 and several are on the way. This acceleration of approvals shows that researchers have accumulated enough fundamental knowledge to support gene therapy and endorse its feasibility and clinical relevance. Currently targeting rare diseases, gene therapy products will, in the future, concern more common disease, such as cancer, and will be accessible for a larger number of patients. Nevertheless, the production and the price of this therapy is still a great challenge, and has recently conducted to the withdrawn of Glybera (1 million $/treatment). We believe that improvement could come from the delivery strategy of the therapeutic gene. Viral vectors have been commercialized, but their exorbitant production cost, biosafety issues, potential immunogenicity, limit their large-scale production. Up to now, synthetic vectors have failed in clinical trials due to insufficient efficacy and non-specific toxicity, often attributed to their positive charge.
We have recently developed pH-sensitive molecular tweezers, inspired from the biomimetic host-guest chemistry. These structures are inspired from the molecular machine field awarded by the Nobel Price in 2016. We have shown that these tweezers are able to bind a drug at physiological pH and release it at acidic pH. We also incorporated the tweezers in a lipid structure to get pH-sensitive liposomes. These nanocarriers were able to drastically improve the cytosolic delivery of hydrophilic drugs and nucleic acids in vitro and in vivo. Nevertheless, their cationic charge still limited their in vivo efficacy.
In this project, we want to develop molecular tweezers to catch and release DNA. In a first step, they will be designed for non-specific binding of nucleic acids, and will be used as a non-cationic delivery system for gene therapy products. They will be synthesized, characterized, and compared in vitro and in vivo to the latest cationic systems. In a second step, we will design DNA tweezers for the specific recognition of sequences, mismatches or trinucleotide repeats. These defects in genomic DNA are associated with a number of genetic disease such as Huntington disease or muscular dystrophy. The specificity of such tweezers will be optimized in vitro. Then, a chip-base biosensor will be developed and used as a diagnostic tool for DNA defects and genetic diseases.